Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase 2/3 Study to Compare the Efficacy and Safety of Masitinib.
Phase of Trial: Phase II/III
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Masitinib (Primary) ; Riluzole
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 10 Jun 2017 Biomarkers information updated
- 20 Apr 2017 Status changed from active, no longer recruiting to completed.
- 29 Sep 2016 Results of interim analysis published in an AB Science media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History